

Supporting Information for
**Preparation of 2-Amino-3-arylindoles via Pd-Catalyzed Coupling
between 3-Diazoindolin-2-imines and Arylboronic Acids as well as
Their Extension to 3-Aryl-3-fluoroindolin-2-imines**

Hualong Ding, Songlin Bai, Ping Lu,* Yanguang Wang*

Department of Chemistry, Zhejiang University, Hangzhou 310027, P. R. China

pinglu@zju.edu.cn; orgwyg@zju.edu.cn

Contents

General Information.....	S2
Table S1. Screening of the reaction conditions.....	S3
General Procedure for the Synthesis of 3	S5
Preparation of 3a in 1 mmol Scale.....	S5
General Procedure for the Synthesis of 5	S5
General Procedure for the Synthesis of 6	S6
MS of the Combined Species	
from Triethylamine and(3,5-Dimethoxyphenyl)boronic Acid.....	S8
ORTEP diagram and Crystal Parameters of 3a , 4 and 6a	S9
Characterization Data for Products.....	S12
The ¹ H and ¹³ C NMR Spectra of Products.....	S26

General Information


Unless otherwise mentioned, solvents and reagents were purchased from commercial sources and used as received. ^1H NMR spectra were obtained on 500 or 400 MHz spectrometer at room temperature. The chemical shifts were reported relative to internal TMS (0 ppm) in CDCl_3 or $(\text{CD}_3)_2\text{SO}$. The following abbreviations were used to describe peak patterns when appropriate: b = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. Coupling constants (J values) were reported in Hertz unit (Hz). ^{13}C NMR spectra were recorded on 100 or 125 MHz spectrometer and the chemical shifts were referenced to the central line of the triplet of CDCl_3 (77.00 ppm) or the center line of the heptet of $(\text{CD}_3)_2\text{SO}$ (40.0 ppm). Infrared spectra were obtained on FTIR spectrometer. All high-resolution mass spectra (HRMS) data were obtained by using EI ionization on time-of-flight (TOF) mass spectrometer or ESI ionization on LCMS-IT-TOF mass spectrometer. Melting points were measured with a micro melting point apparatus. Flash column chromatography was performed employing 300-400 mesh silica gel. Thin layer chromatography (TLC) was performed on silica gel HSGF254.

Substrates **1** were prepared according to the published methods.¹

References

1. (a) Y. P. Xing, G. R. Sheng, J. Wang, P. Lu, Y. G. Wang, *Org. Lett.* **2014**, *16*, 1244–1247. (b) G. R. Sheng, K. Huang, Z. H. Chi, H. L. Ding, Y. P. Xing, P. Lu, Y. G. Wang, *Org. Lett.* **2014**, *16*, 5096–5099.

Table S1. Screening of the reaction conditions^a




entry	catalyst	base	acid	solvent	temp (°C)	time(h)	yield(%) ^b
1	Pd(OAc) ₂	KF	CH ₃ COOH	DCE	50	2	27
2	Pd(PPh ₃) ₄	KF	CH ₃ COOH	DCE	50	2	trace
3	PdCl ₂	KF	CH ₃ COOH	DCE	50	2	ND
4	Pd(OH) ₂	KF	CH ₃ COOH	DCE	50	2	ND
5	Pd(OAc) ₂	K ₂ HPO ₄	NONE	DCE	50	2	43
6	Pd(OAc) ₂	K ₂ HPO ₄	NONE	CHCl ₃	50	2	44
7	Pd(OAc) ₂	K ₂ HPO ₄	NONE	DCM	50	2	34
8	Pd(OAc) ₂	K ₂ HPO ₄	NONE	THF	50	2	20
9	Pd(OAc) ₂	K ₂ HPO ₄	NONE	PhMe	50	2	29
10	Pd(OAc) ₂	K ₂ HPO ₄	NONE	MeCN	50	2	trace
11	Pd(OAc) ₂	K ₂ HPO ₄	NONE	1,4-dioxane	50	2	18
12	Pd(OAc) ₂	K ₂ HPO ₄	NONE	DMF	50	2	ND
13	Pd(OAc) ₂	K ₂ CO ₃	CH ₃ COOH	CHCl ₃	50	2	49
14	Pd(OAc) ₂	NaOAc	CH ₃ COOH	CHCl ₃	50	2	12
15	Pd(OAc) ₂	Na ₂ CO ₃	CH ₃ COOH	CHCl ₃	50	2	16
16	Pd(OAc) ₂	Cs ₂ CO ₃	CH ₃ COOH	CHCl ₃	50	2	10
17	Pd(OAc) ₂	NaHCO ₃	NONE	CHCl ₃	50	2	42
18	Pd(OAc) ₂	KH ₂ PO ₄	NONE	CHCl ₃	50	2	44
19	Pd(OAc) ₂	K ₂ CO ₃	NONE	CHCl ₃	50	2	trace
20	Pd(OAc) ₂	K ₂ HPO ₄	CH ₃ COOH	CHCl ₃	50	2	47
21	Pd(OAc) ₂	K ₂ CO ₃	CF ₃ COOH	CHCl ₃	50	2	56
22	Pd(OAc) ₂	K ₂ CO ₃	CF ₃ COOH	CHCl ₃	reflux	1	14
23	Pd(OAc) ₂	K ₂ CO ₃	CF ₃ COOH	CHCl ₃	rt	12	58
24	Pd(OAc) ₂	K ₂ CO ₃	CF ₃ COOH	CHCl ₃	0	12	56
25	Pd(OAc) ₂	K ₂ CO ₃	HClO ₄ ^c	CHCl ₃	rt	12	65
26	Pd(OAc) ₂	Et ₃ N	HClO ₄ ^c	CHCl ₃	rt	12	67

27	Pd(OAc) ₂	Pyridine	HClO ₄ ^c	CHCl ₃	rt	12	NR
28	Pd(OAc) ₂	DIEA	HClO ₄ ^c	CHCl ₃	rt	12	34
29	Pd(OAc) ₂	DBU	HClO ₄ ^c	CHCl ₃	rt	12	NR
30	Pd(OAc) ₂	(Me ₂ NCH ₂) ₂	HClO ₄ ^c	CHCl ₃	rt	12	18
31	Pd(OAc) ₂	Et ₃ N(5equiv)	HClO ₄ ^c (5equiv)	CHCl ₃	rt	12	78
32	Pd(OAc) ₂	Et ₃ N(6equiv)	HClO ₄ ^c (6equiv)	CHCl ₃	rt	12	81
33	Pd(OAc) ₂	Et ₃ N(7equiv)	HClO ₄ ^c (7equiv)	CHCl ₃	rt	12	80
34	NONE	Et ₃ N(6equiv)	HClO ₄ ^c (6equiv)	CHCl ₃	rt	12	ND
35	Pd(OAc) ₂	Et ₃ N(6equiv)	NONE	CHCl ₃	rt	12	25
36	Pd(OAc) ₂	NONE	HClO ₄ ^c (6equiv)	CHCl ₃	rt	12	21

^a Reaction condition: **1a** (0.2 mmol), **2a** (0.6 mmol), Pd catalyst (10 mol %), base (3.0 equiv), acid (3.0equiv), solvent (2 mL). ^bIsolated yield. ^c 70% aqueous HClO₄ was used.

General Procedure for the Synthesis of 3




To a solution of **1** (0.2 mmol) and **2** (3.0 equiv) in CHCl_3 (2 mL) was added triethylamine (165 μL , 6.0 equiv), HClO_4 (70% aq, 68 μL , 6.0 equiv), and $\text{Pd}(\text{OAc})_2$ (4.4 mg, 0.1 equiv). Then, the reaction mixture was stirred at room temperature for 12 h (24 h for **3e** and **3f**; 36 h for **3h**, **3q**, **3r**, **3v** and **3A**; 3 d for **3t**). After the reaction completed, the solvent was removed in vacuum and the residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1, v/v) to give pure product.

Preparation of 3a in 1 mmol Scale

To a solution of **1a** (1.0 mmol, 326 mg) and **2a** (3.0 equiv) in CHCl_3 (10 mL) was added triethylamine (832 μL , 6.0 equiv), HClO_4 (70% aq, 342 μL , 6.0 equiv), and $\text{Pd}(\text{OAc})_2$ (22.4 mg, 0.1 equiv). Then the reaction mixture was stirred for 12 h at room temperature. After the reaction completed, the solvent was removed in vacuum and the residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1, v/v) to give product **3a** (305 mg, 78% yield).

General Procedure for the Synthesis of 5




Method A: To a stirring solution of **3a** (78 mg, 0.2 mmol), *t*-BuOK (34 mg, 1.5 equiv) in MeCN (2 mL) was added electrophile (E^+ = benzyl bromide, methyl iodide or allyl bromide) (1.5 equiv) at room temperature. The mixture was stirred at room temperature for 2 h. After the reaction

completed (checked by TLC), the mixture was concentrated under vacuum and filtered through a plug of silica gel (DCM). The solvent was removed in vacuum and the residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 6:1, v/v) to give pure products **5a-c**.


Method B: To a solution of **3a** (78 mg, 0.2 mmol), di-*tert*-butyl dicarbonate (69 μ L, 1.5 equiv) in THF (2 mL) was added Et₃N (83 μ L, 3.0 equiv) and DMAP (3 mg, 0.1 equiv) at a sealed tube. The mixture was stirred at 110 °C for 20 h. After the reaction completed, the solvent was removed in vacuum and the residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 6:1, v/v) to give pure **5d**.

General Procedure for the Synthesis of **6**



To a stirring solution of **3** (0.2 mmol), K₂CO₃ (69 mg, 2.5 equiv) and hydroquinidine (DHQD) (6 mg, 0.1 equiv) in MeCN (2 mL) was added NFSI (76 mg, 1.2 equiv) at 0 °C. The reaction mixture was stirred for 2 h. After the reaction completed, the solvent was removed in vacuum and the residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 4:1, v/v) to give pure **6**.

Optimizing the enantiomer excess of **6a**: To a stirring solution of **3a** (39 mg, 0.1 mmol), K₂CO₃ (20 mg, 1.0 equiv) and (DHQD)₂PHAL (7 mg, 0.1 equiv) in MeCN (1 mL) was added NFSI (38 mg, 1.2 equiv) at -40 °C. After the reaction mixture was stirred for 24 h, the solvent was quenched with water and the aqueous was extracted with DCM (3 $\times$ 10 mL). The combined extracts were washed with water and dried over anhydrous Na₂SO₄. Evaporation of solvents and the residue was purified by flash column chromatography on silica gel (petroleum ether/ethyl acetate = 4:1, v/v) to give **6a** as a white solid (39 mg, 97% yield, 60% ee). HPLC: Chiralcel AD-H column (250 mm); Hexane/*i*-PrOH = 75/25; flow = 0.8 ml/min; detected at 254 nm; Retention time: 23.1 min, 31.1 min (major).




面积百分比报告

排序 : 信号
乘积因子 : 1.0000
稀释因子 : 1.0000
内标使用乘积因子和稀释因子

信号 1: VWD1 A, 波长=254 nm

峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 mAU * s	峰高 [mAU]	峰面积 %
1	22.765	MM	0.9323	4245.05859	75.88873	49.0068
2	30.618	MM	1.1806	4417.12109	62.35790	50.9932

总量 : 8662.17969 138.24662



面积百分比报告


排序 : 信号
乘积因子 : 1.0000
稀释因子 : 1.0000
内标使用乘积因子和稀释因子

信号 1: VWD1 A, 波长=254 nm


峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 mAU * s	峰高 [mAU]	峰面积 %
1	23.072	MM	1.0680	909.61407	14.19493	19.9063
2	31.120	MM	1.3007	3659.85571	46.89703	80.0937

总量 : 4569.46979 61.09196

MS of the Combined Species from Triethylamine and (3,5-Dimethoxyphenyl)-boronic Acid




ORTEP diagram and Crystal Parameters of 3a, 4 and 6a



Datablock: I

Bond precision:	C-C = 0.0034 Å	Wavelength=0.71073
Cell:	a=28.1291 (17) alpha=90	b=11.3338 (5) beta=91.255 (5)
Temperature:	293 K	c=14.8299 (8) gamma=90
Volume	Calculated 4726.8 (4)	Reported 4726.8 (4)
Space group	C 2/c	C 1 2/c 1
Hall group	-C 2yc	-C 2yc
Moiety formula	C23 H22 N2 O2 S	C23 H22 N2 O2 S
Sum formula	C23 H22 N2 O2 S	C23 H22 N2 O2 S
Mr	390.49	390.49
Dx, g cm ⁻³	1.097	1.097
Z	8	8
Mu (mm ⁻¹)	0.155	0.155
F000	1648.0	1648.0
F000'	1649.62	
h, k, lmax	33, 13, 17	33, 13, 17
Nref	4333	4254
Tmin, Tmax	0.927, 0.940	0.963, 1.000
Tmin'	0.927	
Correction method= # Reported T Limits: Tmin=0.963 Tmax=1.000		
AbsCorr = MULTI-SCAN		
Data completeness= 0.982	Theta (max)= 25.350	
R (reflections)= 0.0464 (3144)	wR2 (reflections)= 0.1369 (4254)	
S = 1.081	Npar= 260	



Datablock: 170319_dhl08378a_2

Bond precision: C-C = 0.0065 Å

Wavelength=0.71073

Cell: a=6.8692 (7) b=7.4511 (9) c=15.6394 (18)
 alpha=85.058 (9) beta=80.243 (9) gamma=68.404 (10)
 Temperature: 293 K

	Calculated	Reported
Volume	733.27 (15)	733.26 (15)
Space group	P -1	P -1
Hall group	-P 1	-P 1
Moiety formula	C16 H14 N2 O3 S	C16 H14 N2 O3 S
Sum formula	C16 H14 N2 O3 S	C16 H14 N2 O3 S
Mr	314.35	314.35
Dx, g cm ⁻³	1.424	1.424
Z	2	2
Mu (mm ⁻¹)	0.235	0.235
F000	328.0	328.0
F000'	328.39	
h, k, lmax	8, 8, 18	8, 8, 18
Nref	2683	2667
Tmin, Tmax	0.937, 0.977	0.793, 1.000
Tmin'	0.932	

Correction method= # Reported T Limits: Tmin=0.793 Tmax=1.000
 AbsCorr = MULTI-SCAN

Data completeness= 0.994


Theta(max)= 25.346

R(reflections)= 0.0688 (1740)

wR2(reflections)= 0.1969 (2667)

S = 1.059

Npar= 201




Datablock: dhl330b

Bond precision:	C-C = 0.0045 Å		Wavelength=0.71073
Cell:	a=8.5856 (5)	b=26.6604 (15)	c=9.0241 (6)
	alpha=90	beta=98.396 (2)	gamma=90
Temperature:	296 K		
	Calculated	Reported	
Volume	2043.4 (2)	2043.4 (2)	
Space group	P 21/n	P 1 21/n 1	
Hall group	-P 2yn	-P 2yn	
Moiety formula	C23 H21 F N2 O2 S	C23 H21 F N2 O2 S	
Sum formula	C23 H21 F N2 O2 S	C23 H21 F N2 O2 S	
Mr	408.48	408.48	
Dx, g cm-3	1.328	1.328	
Z	4	4	
Mu (mm-1)	0.189	0.189	
F000	856.0	856.0	
F000'	856.88		
h, k, lmax	11, 34, 11	11, 34, 11	
Nref	4689	4662	
Tmin, Tmax	0.900, 0.952	0.902, 0.952	
Tmin'	0.900		
Correction method= # Reported T Limits: Tmin=0.902 Tmax=0.952			
AbsCorr = MULTI-SCAN			
Data completeness= 0.994		Theta(max)= 27.470	
R(reflections)= 0.0659 (2797)		wR2(reflections)= 0.1314 (4662)	
S = 1.002		Npar= 266	


Characterization Data for All Products

4-Methyl-N-(1-methyl-3-(p-tolyl)-1H-indol-2-yl)benzenesulfonamide (3a)




White solid (63 mg, 81%); m.p. 157.3 – 158.4 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.52 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.32 – 7.28 (m, 1H), 7.19 (d, J = 8.4 Hz, 2H), 7.13 – 7.09 (m, 1H), 6.96 (d, J = 8.0 Hz, 2H), 6.92 (s, 1H), 6.83 – 6.79 (m, 4H), 3.91 (s, 3H), 2.35 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.6, 135.5, 135.0, 134.8, 129.9, 128.9, 128.9, 128.5, 127.2, 126.3, 125.1, 122.9, 120.1, 119.7, 112.8, 109.9, 30.0, 21.5, 21.2; IR (neat) ν 3269, 3050, 2922, 1598, 1567, 1471, 1373, 1330, 1259, 1162, 1091 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_2\text{S}]$: 390.1402; found: 390.1398.

N-(1-Ethyl-3-(p-tolyl)-1H-indol-2-yl)-4-methylbenzenesulfonamide (3b)




White solid (64 mg, 79%); m.p. 151.4 – 152.3 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.51 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.30 – 7.26 (m, 1H), 7.19 (d, J = 8.4 Hz, 2H), 7.11 – 7.03 (m, 2H), 6.94 (d, J = 8.0 Hz, 2H), 6.83 (d, J = 8.0 Hz, 2H), 6.79 (d, J = 8.0 Hz, 2H), 4.49 (q, J = 7.2 Hz, 2H), 2.34 (s, 3H), 2.29 (s, 3H), 1.48 (t, J = 7.2 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.5, 135.4, 134.9, 134.0, 130.0, 128.9, 128.8, 128.6, 127.2, 125.5, 125.4, 122.9, 119.9, 119.0, 113.3, 110.2, 38.0, 21.5, 21.2, 14.8; IR (neat) ν 3258, 3054, 2979, 1581, 1557, 1510, 1488, 1470, 1403, 1331, 1284, 1162, 1087 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_2\text{S}]$: 404.1558; found: 404.1558.

N-(1-Isopropyl-3-(p-tolyl)-1H-indol-2-yl)-4-methylbenzenesulfonamide (3c)




White solid (69 mg, 83%); m.p. 154.7 – 155.8 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.26 – 7.22 (m, 1H), 7.17 (d, J = 8.0 Hz, 2H), 7.08 – 7.05 (m, 1H), 6.98 – 6.93 (m, 3H), 6.79 (d, J = 8.4 Hz, 4H), 5.35 – 5.24 (m, 1H), 2.34 (s, 3H), 2.30 (s, 3H), 1.73 (d, J = 7.2 Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.5, 135.4, 134.8, 132.7, 130.0, 128.9, 128.8, 128.6, 127.2, 126.1, 125.4, 122.3, 120.0, 119.5, 112.8, 112.4, 46.9, 21.5, 21.2, 21.1; IR (neat) ν 3262, 3051, 2978, 1574, 1510, 1470, 1404, 1336, 1284, 1162, 1086, 1008 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{25}\text{H}_{26}\text{N}_2\text{O}_2\text{S}]$: 418.1715; found: 418.1714.

N-(1-Benzyl-3-(p-tolyl)-1H-indol-2-yl)-4-methylbenzenesulfonamide (3d)




White solid (69 mg, 74%); m.p. 116.3 – 117.5 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.55 (d, J = 8.0 Hz, 1H), 7.30 – 7.20 (m, 7H), 7.11 – 7.07 (m, 3H), 6.96 (d, J = 8.0 Hz, 2H), 6.87 (d, J = 8.0 Hz, 2H), 6.81 – 6.77 (m, 3H), 5.66 (s, 3H), 2.34 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.6, 137.7, 135.6, 135.0, 134.8, 129.8, 128.9, 128.8, 128.7, 128.6, 127.3, 127.3, 126.6, 125.9, 125.4, 123.3, 120.3, 119.9, 114.2, 110.6, 46.6, 21.5, 21.2; IR (neat) ν 3258, 3030, 2921, 1573, 1510, 1496, 1463, 1400, 1333, 1304, 1209, 1162, 1091, 1008 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{29}\text{H}_{26}\text{N}_2\text{O}_2\text{S}]$: 466.1715; found: 466.1707.

N-(1-Methyl-3-(p-tolyl)-1H-indol-2-yl)methanesulfonamide (3e)




White solid (19 mg, 30%); m.p. 154.0 – 154.9 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.70 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 2H), 7.38 – 7.28 (m, 4H), 7.19 – 7.15 (m, 1H), 6.96 – 6.95 (m, 1H), 3.82 (s, 3H), 2.41 (s, 3H), 2.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 136.7, 135.0, 130.4, 129.9, 129.0, 125.8, 124.9, 123.3, 120.4, 119.8, 113.4, 110.0, 39.9, 29.6, 21.2; IR (neat) ν 3254, 3027, 2927, 1567, 1510, 1471, 1434, 1373, 1328, 1158, 1090, 976 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{17}\text{H}_{18}\text{N}_2\text{O}_2\text{S}]$: 314.1089; found: 314.1094.

4-Methoxy-N-(1-methyl-3-(p-tolyl)-1H-indol-2-yl)benzenesulfonamide (3f)




White solid (40 mg, 49%); m.p. 197.7 – 198.5 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.53 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.32 – 7.28 (m, 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.13 – 7.09 (m, 1H), 6.98 – 6.94 (m, 3H), 6.84 (d, J = 8.0 Hz, 2H), 6.47 (d, J = 9.2 Hz, 2H), 3.91 (s, 3H), 3.79 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.1, 135.5, 135.1, 130.0, 129.3, 129.2, 129.0, 128.5, 126.4, 125.1, 122.9, 120.1, 119.7, 113.5, 112.7, 109.9, 55.3, 30.0, 21.1; IR (neat) ν 3280, 3060, 2917, 1596, 1575, 1497, 1459, 1373, 1329, 1261, 1179, 1158, 1092, 1029 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_3\text{S}]$: 406.1351; found: 406.1349.

4-Fluoro-N-(1-methyl-3-(p-tolyl)-1H-indol-2-yl)benzenesulfonamide (3g)




White solid (56 mg, 71%); m.p. 134.4 – 135.4 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.54 (d, J = 8.0 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.34 – 7.28 (m, 3H), 7.14 – 7.10 (m, 1H), 7.04 – 6.99 (m, 3H), 6.85 (d, J = 7.6 Hz, 2H), 6.66 (dd, $J_1 = J_2$ = 8.4 Hz, 2H), 3.91 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.3 (d, J = 253.3 Hz), 164.0, 135.9, 135.1, 133.7, 130.0, 129.9 (d, J = 9.6 Hz), 129.2, 128.4, 125.8, 124.9, 123.2, 120.3, 119.8, 115.5 (d, J = 22.6 Hz), 113.1, 109.9, 29.9, 21.0; IR (neat) ν 3273, 3062, 2922, 1591, 1566, 1493, 1470, 1373, 1331, 1236, 1169, 1154, 1090, 1014 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{22}\text{H}_{19}\text{FN}_2\text{O}_2\text{S}]$: 394.1151; found: 394.1149.

N-(1-Methyl-3-(p-tolyl)-1H-indol-2-yl)-4-nitrobenzenesulfonamide (3h)



Yellow solid (14 mg, 16%); m.p. 179.2 – 180.3 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 8.8 Hz, 2H), 7.40 (d, J = 8.4 Hz, 1H), 7.36 – 7.32 (m, 1H), 7.15 – 7.11 (m, 2H), 6.92 (d, J = 7.6 Hz, 2H), 6.82 (d, J = 8.0 Hz, 2H), 3.93 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 150.0, 143.4, 136.5, 135.1, 129.7, 129.2, 128.5, 128.4, 124.7, 124.6, 123.6, 123.3, 120.5, 119.9, 113.5, 110.0, 29.9, 21.0; IR (neat) ν 3287, 3101, 2917, 1557, 1531, 1471, 1432, 1348, 1307, 1167, 1140, 1089, 1014 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{22}\text{H}_{19}\text{N}_3\text{O}_4\text{S}]$: 421.1096; found: 421.1099.

N-(1-Methyl-3-(p-tolyl)-1H-indol-2-yl)benzenesulfonamide (3i)




White solid (60 mg, 80%); m.p. 85.2 – 86.4 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.52 (d, J = 8.0 Hz, 1H), 7.39 (d, J = 8.0 Hz, 1H), 7.34 – 7.29 (m, 4H), 7.13 – 7.05 (m, 3H), 6.99 – 6.93 (m, 3H), 6.80 (d, J = 7.6 Hz, 2H), 3.91 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 137.9, 135.6, 135.1, 132.7, 129.8, 129.2, 128.5, 128.4, 127.3, 126.1, 125.1, 123.0, 120.1, 119.7, 113.0, 109.9, 30.0, 21.1; IR (neat) ν 3268, 3059, 2921, 1567, 1510, 1470, 1447, 1373, 1329, 1222, 1164, 1090 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{22}\text{H}_{20}\text{N}_2\text{O}_2\text{S}]$: 376.1245; found: 376.1248.

N-(5-Fluoro-1-methyl-3-(p-tolyl)-1H-indol-2-yl)-4-methylbenzenesulfonamide (3j)


Light yellow solid (69 mg, 85%); m.p. 208.7 – 209.8 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.29 (dd, J_1 = 8.8 Hz, J_2 =

4.4 Hz, 1H), 7.20 – 7.15 (m, 3H), 7.07 – 7.01 (m, 2H), 6.96 (d, $J = 7.6$ Hz, 2H), 6.82 (d, $J = 8.0$ Hz, 2H), 6.77 (d, $J = 8.0$ Hz, 2H), 3.89 (s, 3H), 2.34 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.3 (d, $J = 234.0$ Hz), 143.8, 135.8, 134.7, 131.6, 129.5, 129.0, 128.3, 127.6, 127.2, 125.3 (d, $J = 9.9$ Hz), 112.9 (d, $J = 4.9$ Hz), 111.5 (d, $J = 26.1$ Hz), 110.7 (d, $J = 9.3$ Hz), 104.5 (d, $J = 23.8$ Hz), 30.2, 21.5, 21.1; IR (neat) ν 3278, 3048, 2916, 1624, 1597, 1557, 1488, 1436, 1375, 1324, 1258, 1162, 1089 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{23}\text{H}_{21}\text{FN}_2\text{O}_2\text{S}]$: 408.1308; found: 408.1308.




N-(5-Chloro-1-methyl-3-(p-tolyl)-1H-indol-2-yl)-4-methylbenzenesulfonamide (3k)

Light yellow solid (71 mg, 84%); m.p. 187.2 – 188.3 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.46 (d, $J = 1.6$ Hz, 1H), 7.28 (d, $J = 8.4$ Hz, 1H), 7.23 (dd, $J_1 = 8.8$ Hz, $J_2 = 2.0$ Hz, 1H), 7.18 (d, $J = 8.0$ Hz, 2H), 7.10 (b, 1H), 6.96 (d, $J = 8.0$ Hz, 2H), 6.82 (d, $J = 8.0$ Hz, 2H), 6.77 (d, $J = 8.0$ Hz, 2H), 3.88 (s, 3H), 2.34 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.8, 135.9, 134.7, 133.4, 129.2, 129.0, 129.0, 128.4, 127.4, 127.2, 126.0, 126.0, 123.3, 119.1, 112.6, 111.0, 30.2, 21.5, 21.1; IR (neat) ν 3263, 3028, 2921, 1598, 1563, 1472, 1433, 1372, 1327, 1287, 1162, 1091 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{23}\text{H}_{21}\text{ClN}_2\text{O}_2\text{S}]$: 424.1012; found: 424.1012.




N-(5-Bromo-1-methyl-3-(p-tolyl)-1H-indol-2-yl)-4-methylbenzenesulfonamide (3l)

Light yellow solid (72 mg, 77%); m.p. 178.0 – 179.3 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.62 (d, $J = 2.0$ Hz, 1H), 7.37 (dd, $J_1 = 8.8$ Hz, $J_2 = 1.6$ Hz, 1H), 7.25 (d, $J = 2.0$ Hz, 1H), 7.17 (d, $J = 8.4$ Hz, 2H), 7.03 (b, 1H), 6.97 (d, $J = 8.0$ Hz, 2H), 6.82 (d, $J = 8.0$ Hz, 2H), 6.76 (d, $J = 8.0$ Hz, 2H), 3.88 (s, 3H), 2.34 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.8, 135.9, 134.6, 133.6, 129.2, 129.0, 129.0, 128.4, 127.2, 127.2, 126.7, 125.8, 122.1, 113.5, 112.5, 111.4, 30.2, 21.5, 21.2; IR (neat) ν 3265, 3021, 2921, 1598, 1563, 1471, 1431, 1376, 1326, 1287, 1162, 1090 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{23}\text{H}_{21}\text{BrN}_2\text{O}_2\text{S}]$: 468.0507; found: 468.0499.




N-(1,5-Dimethyl-3-(p-tolyl)-1H-indol-2-yl)-4-methylbenzenesulfonamide (3m)

Light yellow liquid (65 mg, 80 %); ^1H NMR (400 MHz, CDCl_3) δ 7.29 – 7.25 (m, 2H), 7.18 (d, $J = 8.4$ Hz, 2H),




7.13 – 7.11 (m, 1H), 6.96 (d, $J = 7.6$ Hz, 3H), 6.80 (t, $J = 7.6$ Hz, 4H), 3.87 (s, 3H), 2.39 (s, 3H), 2.34 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.6, 135.4, 134.8, 133.4, 130.1, 129.4, 128.9, 128.8, 128.5, 127.2, 126.2, 125.2, 124.6, 119.2, 112.3, 109.6, 30.0, 21.5, 21.4, 21.2; IR (neat) ν 3264, 3027, 2920, 1567, 1493, 1435, 1392, 1377, 1327, 1296, 1161, 1090 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_2\text{S}]$: 404.1558; found: 404.1559.

N-(5-Methoxy-1-methyl-3-(p-tolyl)-1H-indol-2-yl)-4-methylbenzenesulfonamide (3n)




Colorless oil (70 mg, 83%); ^1H NMR (400 MHz, CDCl_3) δ 7.28 – 7.26 (m, 1H), 7.19 (d, $J = 8.4$ Hz, 2H), 6.98 – 6.95 (m, 5H), 6.83 – 6.79 (m, 4H), 3.87 (s, 3H), 3.76 (s, 3H), 2.34 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 154.5, 143.5, 135.4, 134.9, 130.3, 130.1, 128.9, 128.4, 127.2, 126.5, 125.3, 113.4, 112.6, 110.7, 101.1, 55.8, 30.0, 21.5, 21.1; IR (neat) ν 3271, 3024, 2922, 1622, 1593, 1487, 1455, 1397, 1327, 1262, 1197, 1162, 1090, 1033 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{24}\text{H}_{22}\text{N}_2\text{O}_3\text{S}]$: 420.1508; found: 420.1508.

4-Methyl-N-(1-methyl-3-phenyl-1H-indol-2-yl)benzenesulfonamide (3o)



White solid (50 mg, 67%); m.p. 171.4 – 172.3 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.53 (d, $J = 8.0$ Hz, 1H), 7.39 (d, $J = 8.0$ Hz, 1H), 7.32 – 7.29 (m, 1H), 7.19 – 7.09 (m, 7H), 6.94 – 6.92 (m, 2H), 6.80 (d, $J = 8.4$ Hz, 2H), 3.91 (s, 3H), 2.28 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.6, 135.0, 134.5, 132.9, 129.1, 128.7, 128.2, 127.2, 126.4, 125.8, 125.0, 123.0, 120.2, 119.6, 112.9, 109.9, 30.0, 21.5; IR (neat) ν 3262, 3057, 2923, 1567, 1488, 1392, 1369, 1331, 1259, 1163, 1090 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{22}\text{H}_{20}\text{N}_2\text{O}_2\text{S}]$: 376.1245; found: 376.1241.


N-(3-(4-Fluorophenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide (3p)



White solid (17 mg, 21%); m.p. 171.4 – 172.3 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.48 (d, $J = 8.0$ Hz, 1H), 7.39 (d, $J = 8.0$ Hz, 1H), 7.34 – 7.30 (m, 1H), 7.23 (d, $J = 8.4$ Hz, 2H), 7.14 – 7.10 (m, 1H), 7.05 (b, 1H), 6.94 – 6.82 (m, 6H), 3.90 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 161.3 (d, $J = 243.9$ Hz), 143.9, 135.0, 135.0, 130.2 (d, $J = 7.9$


Hz), 129.1, 129.0(d, $J = 3.1$ Hz), 127.2, 126.2, 125.0, 123.2, 120.3, 119.5, 115.1 (d, $J = 21.3$ Hz), 112.2, 110.0, 29.9, 21.5; IR (neat) ν 3269, 3061, 2926, 1598, 1564, 1506, 1471, 1373, 1330, 1220, 1185, 1091, 1017 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{22}\text{H}_{19}\text{FN}_2\text{O}_2\text{S}]$: 394.1151; found: 394.1156.

N-(3-(4-Chlorophenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide (3q)




White solid (20 mg, 25%); m.p. 143.9 – 145.4 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.50 (d, $J = 8.0$ Hz, 1H), 7.40 (d, $J = 8.0$ Hz, 1H), 7.35 – 7.31 (m, 1H), 7.23 (d, $J = 8.4$ Hz, 2H), 7.15 – 7.07 (m, 4H), 6.92 – 6.87 (m, 4H), 3.91 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.1, 135.0, 135.0, 131.8, 131.5, 129.9, 129.1, 128.3, 127.2, 126.3, 124.7, 123.3, 120.5, 119.4, 112.1, 110.1, 29.9, 21.5; IR (neat) ν 3265, 3060, 2947, 1598, 1557, 1492, 1471, 1393, 1331, 1256, 1163, 1092, 1014 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{22}\text{H}_{19}\text{ClN}_2\text{O}_2\text{S}]$: 410.0856; found: 410.0850.

N-(3-(4-Bromophenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide (3r)




White solid (17 mg, 19%); m.p. 167.6 – 168.8 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.49 (d, $J = 8.0$ Hz, 1H), 7.40 (d, $J = 8.0$ Hz, 1H), 7.35 – 7.31 (m, 1H), 7.27 – 7.22 (m, 4H), 7.15 – 7.11 (m, 1H), 7.07 (b, 1H), 6.89 – 6.84 (m, 4H), 3.91 (s, 3H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 144.2, 135.0, 135.0, 132.0, 131.3, 130.2, 129.1, 127.2, 126.3, 124.7, 123.3, 120.5, 119.9, 119.4, 112.1, 110.1, 29.9, 21.6; IR (neat) ν 3270, 3060, 2925, 1597, 1558, 1471, 1434, 1392, 1330, 1258, 1162, 1090, 1010 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{22}\text{H}_{19}\text{BrN}_2\text{O}_2\text{S}]$: 454.0351; found: 454.0344.

N-(3-(4-Methoxyphenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide (3s)



White solid (64 mg, 79%); m.p. 195.8 – 197.1 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.50 (d, $J = 8.0$ Hz, 1H), 7.38 (d, $J = 8.0$ Hz, 1H), 7.32 – 7.28 (m, 1H), 7.22 (d, $J = 8.4$ Hz, 2H), 7.13 – 7.09 (m, 1H), 6.97 (s, 1H), 6.86 – 6.83 (m, 4H), 6.69 (d, $J = 8.8$ Hz, 2H), 3.90 (s, 3H), 3.82 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.0, 143.6, 135.0, 135.0, 129.7, 129.0, 127.2, 126.1, 125.3, 125.2, 123.0, 120.1, 119.7, 113.7, 112.6, 109.9, 55.2, 30.0, 21.5; IR (neat) ν 3269, 3057, 2935, 1730, 1619, 1557, 1506, 1468, 1391, 1280, 1253, 1161, 1084, 1032 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_3\text{S}]$: 406.1351; found: 406.1348.

N-(3-([1,1'-Biphenyl]-4-yl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide (3t)




Light yellow solid (30 mg, 33%); m.p. 186.7 – 187.8 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.61 – 7.59 (m, 3H), 7.51 – 7.47 (m, 2H), 7.42 – 7.31 (m, 5H), 7.22 (d, J = 8.0 Hz, 2H), 7.17 – 7.13 (m, 1H), 7.03 (d, J = 8.4 Hz, 2H), 6.99 (b, 1H), 6.80 (d, J = 8.0 Hz, 2H), 3.94 (s, 3H), 2.18 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.8, 140.7, 138.7, 135.1, 134.8, 132.0, 129.0, 128.9, 128.9, 127.3, 127.2, 126.8, 126.7, 126.5, 125.0, 123.1, 120.3, 119.7,

112.5, 110.0, 30.0, 21.5; IR (neat) ν 3262, 3057, 2923, 1596, 1567, 1487, 1393, 1331, 1257, 1163, 1090 cm^{-1} ;

HRMS (EI): M^+ calcd for $[\text{C}_{28}\text{H}_{24}\text{N}_2\text{O}_2\text{S}]$: 452.1558; found: 452.1558.


4-Methyl-N-(1-methyl-3-(*m*-tolyl)-1H-indol-2-yl)benzenesulfonamide (3u)



White solid (63 mg, 81%); m.p. 125.7 – 126.9 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.53 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.32 – 7.28 (m, 1H), 7.20 (d, J = 8.4 Hz, 2H), 7.13 – 7.03 (m, 3H), 6.94 (d, J = 7.6 Hz, 1H), 6.83 (d, J = 8.0 Hz, 2H), 6.76 – 6.73 (m, 2H), 3.92 (s, 3H), 2.29 (s, 3H), 2.25 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.5, 137.8,

135.1, 134.8, 132.8, 129.3, 129.0, 128.2, 127.2, 126.6, 126.4, 125.7, 125.1, 123.0, 120.2, 119.7, 112.8, 109.9, 30.1, 21.5, 21.4; IR (neat) ν 3261, 3057, 2922, 1574, 1470, 1385, 1331, 1284, 1163, 1089 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_2\text{S}]$: 390.1402; found: 390.1412.

4-Methyl-N-(1-methyl-3-(*o*-tolyl)-1H-indol-2-yl)benzenesulfonamide (3v)




White solid (50 mg, 64%); m.p. 171.9 – 173.0 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.38 (d, J = 8.4 Hz, 1H), 7.30 – 7.26 (m, 1H), 7.23 – 7.17 (m, 3H), 7.15 – 7.05 (m, 2H), 7.01 – 6.98 (m, 2H), 6.89 (d, J = 8.0 Hz, 2H), 6.74 (d, J = 7.2 Hz, 2H), 3.92 (s, 3H), 2.34 (s, 3H), 1.80 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.4, 137.0, 135.3, 135.0, 131.9, 130.5, 130.0,

129.3, 126.9, 126.5, 125.5, 125.5, 122.8, 120.4, 119.9, 112.4, 109.9, 30.1, 21.5, 20.2; IR (neat) ν 3258, 3058, 2924, 1599, 1567, 1470, 1371, 1330, 1254, 1163, 1092 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_2\text{S}]$: 390.1402; found: 390.1398.


N-(3-(2-Ethylphenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide (3w)

White solid (68 mg, 85%); m.p. 139.4 – 140.2 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.38 (d, J = 8.4 Hz, 1H), 7.31 – 7.17 (m, 4H), 7.13 (d, J = 7.6 Hz, 1H), 7.06 (t, J = 7.6 Hz, 1H), 6.94 – 6.89 (m, 3H), 6.55 – 6.53 (m, 2H), 3.91 (s,




3H), 2.35 – 2.27 (m, 4H), 2.13– 2.04 (m, 1H), 0.95 (t, $J = 7.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.6, 142.7, 135.5, 135.1, 131.1, 130.9, 129.3, 127.5, 127.2, 127.0, 126.6, 126.1, 125.3, 122.7, 120.1, 119.9, 112.0, 109.8, 30.2, 25.6, 21.5, 14.6; IR (neat) ν 3254, 3059, 2967, 1599, 1557, 1470, 1432, 1390, 1328, 1253, 1162, 1092, 1013 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_2\text{S}]$: 404.1558; found: 404.1554.

N-(3-(2,5-Dimethylphenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide (3x)




Colorless oil (72 mg, 89%); ^1H NMR (400 MHz, CDCl_3) δ 10.29 (s, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.24 – 7.19 (m, 3H), 7.00 – 6.96 (m, 4H), 6.93 – 6.83 (m, 3H), 3.68 (s, 3H), 2.29 (s, 3H), 2.21 (s, 3H), 1.75 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 142.8, 137.8, 134.7, 134.3, 133.9, 132.3, 132.1, 130.0, 129.4, 127.7, 127.6, 126.4, 125.5, 122.6, 120.1, 120.0, 113.1, 110.7, 29.6, 21.5, 21.0, 20.2; IR (neat) ν 3250, 3048, 2922, 1557, 1494, 1470, 1433, 1385, 1328, 1257, 1162, 1091, 1019 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_2\text{S}]$: 404.1558; found: 404.1556.

N-(3-(3,5-Dimethylphenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide (3y)



White solid (67 mg, 83%); m.p. 156.8 – 158.0 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.54 (d, $J = 8.0$ Hz, 1H), 7.38 (d, $J = 8.4$ Hz, 1H), 7.32 – 7.28 (m, 1H), 7.22 (d, $J = 8.0$ Hz, 2H), 7.13 – 7.04 (m, 2H), 6.86 (d, $J = 8.0$ Hz, 2H), 6.76 (s, 1H), 6.56 (s, 2H), 3.91 (s, 3H), 2.29 (s, 3H), 2.22 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.4, 137.7, 135.1, 132.7, 128.9, 127.6, 127.2, 126.4, 126.4, 125.1, 122.9, 120.1, 119.8, 112.8, 109.9, 30.0, 21.5, 21.3; IR (neat) ν 3264, 3030, 2919, 1602, 1557, 1471, 1430, 1379, 1332, 1237, 1163, 1091 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_2\text{S}]$: 404.1558; found: 404.1556.


N-(3-(3,5-Dimethoxyphenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide (3z)



White solid (80 mg, 92%); m.p. 196.4 – 197.2 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.56 (d, $J = 8.0$ Hz, 1H), 7.38 (d, $J = 8.4$ Hz, 1H), 7.33 – 7.29 (m, 1H), 7.26 – 7.24 (m, 2H), 7.14 – 7.10 (m, 2H), 6.87 (d, $J = 8.0$ Hz, 1H), 6.26 (t, $J = 2.4$ Hz, 1H), 6.10 (d, $J = 2.4$ Hz, 2H), 3.91 (s, 3H), 3.74 (s, 6H), 2.21 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 160.7, 143.7, 135.0, 134.9, 134.9, 129.0, 127.3, 126.4, 124.9, 123.0, 120.3, 119.7, 112.8, 109.9, 106.8, 98.0, 55.2, 30.0, 21.3; IR (neat) ν 3272, 3006, 2938, 1594, 1471, 1454, 1424, 1394, 1374, 1337,

1285, 1204, 1158, 1091, 1064 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_4\text{S}]$: 436.1457; found: 436.1462.


4-Methyl-N-(1-methyl-3-(naphthalen-1-yl)-1H-indol-2-yl)benzenesulfonamide (3A)



White solid (49 mg, 57%); m.p. 173.5 – 174.6 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.46 – 7.38 (m, 3H), 7.34 – 7.25 (m, 3H), 7.21 (d, J = 8.0 Hz, 1H), 7.08 – 7.04 (m, 1H), 6.97 – 6.95 (m, 1H), 6.92 (d, J = 8.0 Hz, 2H), 6.83 (b, 1H), 6.47 (d, J = 8.4 Hz, 2H), 4.01 (s, 3H), 2.05 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.0, 135.1, 134.7, 133.7, 131.6, 130.4, 128.8, 128.3, 127.5, 127.5, 127.1, 126.5, 126.1, 126.0, 125.7,

125.7, 125.3, 122.9, 120.4, 120.1, 110.7, 109.9, 30.2, 21.4; IR (neat) ν 3259, 3047, 2944, 1615, 1595, 1557, 1470, 1411, 1366, 1327, 1247, 1162, 1092 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{26}\text{H}_{22}\text{N}_2\text{O}_2\text{S}]$: 426.1402; found: 426.1405.


4-Methyl-N-(1-methyl-3-(naphthalen-2-yl)-1H-indol-2-yl)benzenesulfonamide (3B)



White solid (77 mg, 90%); m.p. 201.7 – 202.9 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.80 – 7.78 (m, 1H), 7.68 – 7.60 (m, 3H), 7.48 – 7.40 (m, 4H), 7.36 – 7.32 (m, 1H), 7.20 – 7.11 (m, 5H), 6.43 (d, J = 8.0 Hz, 2H), 3.95 (s, 3H), 1.91 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.8, 135.1, 134.8, 133.5, 131.8, 130.5, 128.7, 127.8, 127.6, 127.4, 127.2, 127.1, 127.0, 126.6, 126.0, 125.5, 125.1, 123.2, 120.4, 119.7, 113.0, 110.0, 30.0, 21.2; IR (neat) ν 3281,

3051, 2941, 1626, 1599, 1557, 1471, 1397, 1374, 1327, 1162, 1089 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{26}\text{H}_{22}\text{N}_2\text{O}_2\text{S}]$: 426.1402; found: 426.1399.


N-Benzyl-4-methyl-N-(1-methyl-3-(p-tolyl)-1H-indol-2-yl)benzenesulfonamide (5a)



Colorless oil (93 mg, 97%); ^1H NMR (400 MHz, CDCl_3) δ 7.60 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.0 Hz, 1H), 7.26 – 7.15 (m, 7H), 7.10 – 7.05 (m, 3H), 6.94 (d, J = 8.0 Hz, 2H), 6.84 (d, J = 8.0 Hz, 2H), 5.06 (d, J = 13.6 Hz, 1H), 4.21 (d, J = 14.0 Hz, 1H), 3.24 (s, 3H), 2.45 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.7, 136.9, 136.0, 135.6, 135.0, 130.4, 129.6, 129.5, 129.3, 128.9, 128.5, 128.2, 127.8, 126.1, 122.8, 120.0, 119.8, 114.1,


109.8, 55.7, 29.8, 21.6, 21.2; IR (neat) ν 3030, 2943, 1598, 1556, 1470, 1353, 1250, 1162, 1091, 1047 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{30}\text{H}_{28}\text{N}_2\text{O}_2\text{S}]$: 480.1872; found: 480.1877.

N,4-Dimethyl-N-(1-methyl-3-(p-tolyl)-1H-indol-2-yl)benzenesulfonamide (5b)



White solid (76 mg, 94%); m.p. 180.5 – 181.6 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, J = 8.0 Hz, 1H), 7.36 – 7.29 (m, 4H), 7.14 – 7.10 (m, 1H), 7.01 – 6.94 (m, 6H), 3.80 (s, 3H), 3.38 (s, 3H), 2.35 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.2, 136.0, 135.7, 134.9, 131.6, 130.6, 129.1, 129.0, 128.8, 127.3, 125.6, 123.1, 120.1, 120.0, 113.9, 109.7, 40.0, 29.6, 21.5, 21.2; IR (neat) ν 3054, 2922, 1598, 1564, 1510, 1470, 1434, 1385, 1346, 1265, 1162, 1089, 1070 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_2\text{S}]$: 404.1558; found: 404.1555.


N-Allyl-4-methyl-N-(1-methyl-3-(p-tolyl)-1H-indol-2-yl)benzenesulfonamide (5c)



White solid (85 mg, 99%); m.p. 160.8 – 161.3 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.53 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.35 – 7.28 (m, 2H), 7.12 – 7.06 (m, 3H), 6.95 – 6.91 (m, 4H), 5.89–5.79 (m, 1H), 5.06–5.01 (m, 2H), 4.49 (dd, J_1 = 14.4 Hz, J_2 = 6.0 Hz, 1H), 3.88 (dd, J_1 = 14.0 Hz, J_2 = 8.0 Hz, 1H), 3.77 (s, 3H), 2.39 (s, 3H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.5, 136.5, 135.9, 135.0, 132.5, 130.4, 129.8, 129.3, 129.2,

128.8, 128.3, 127.6, 126.4, 125.9, 125.7, 123.0, 120.1, 119.9, 114.4, 109.8, 55.4, 30.3, 21.5, 21.2; IR (neat) ν 3026, 2922, 1598, 1597, 1563, 1508, 1470, 1429, 1386, 1350, 1255, 1163, 1090, 1058 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{26}\text{H}_{26}\text{N}_2\text{O}_2\text{S}]$: 430.1715; found: 430.1719.

tert-Butyl (1-methyl-3-(p-tolyl)-1H-indol-2-yl)(tosyl)carbamate (5d)




White solid (89 mg, 91%); m.p. 171.6 – 172.5 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.74 (d, J = 8.0 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.34– 7.32 (m, 1H), 7.30 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.0 Hz, 2H), 7.18– 7.14 (m, 1H), 7.08 (d, J = 8.0 Hz, 2H), 7.93 (d, J = 8.4 Hz, 2H), 3.81 (s, 3H), 3.38 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.0, 144.0, 136.1, 135.7, 135.4, 130.8, 129.3, 128.8, 128.8, 128.6, 126.6, 125.3, 123.2, 120.3, 120.1,

114.5, 109.8, 85.1, 29.1, 27.9, 21.6, 21.2; IR (neat) ν 2980, 2919, 1738, 1615, 1597, 1567, 1509, 1471, 1433, 1371, 1331, 1287, 1255, 1174, 1148, 1088 cm^{-1} ; HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{28}\text{H}_{31}\text{N}_2\text{O}_4\text{S}]^+$: 491.1999; found: 491.1996.


N-(3-Fluoro-1-methyl-3-(p-tolyl)indolin-2-ylidene)-4-methylbenzenesulfonamide (6a)

White solid (40 mg, 97 %); m.p. 198.6 – 199.4 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.64 (d, J = 8.0 Hz, 2H), 7.38– 7.33 (m, 1H), 7.24 – 7.15 (m, 7H), 7.64 (t, J = 7.6 Hz, 1H), 6.93 (d, J = 7.6 Hz, 1H), 3.44 (s, 3H), 2.38 (s, 3H),



2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.4 (d, $J = 22.6$ Hz), 142.5, 142.4, 139.8, 138.4, 134.1 (d, $J = 26.2$ Hz), 131.0 (d, $J = 2.7$ Hz), 130.3 (d, $J = 20.8$ Hz), 129.2 (d, $J = 0.7$ Hz), 129.0, 126.8, 125.1, 124.5 (d, $J = 2.5$ Hz), 123.8 (d, $J = 6.3$ Hz), 109.6, 96.9 (d, $J = 197.3$ Hz), 29.5, 21.5, 21.3; IR (neat) ν 3058, 3029, 2923, 1633, 1593, 1493, 1471, 1382, 1363, 1316, 1184, 1157, 1088, 1019 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{23}\text{H}_{21}\text{FN}_2\text{O}_2\text{S}]$: 408.1308; found: 408.1309.


N-(1-Benzyl-3-fluoro-3-(p-tolyl)indolin-2-ylidene)-4-methylbenzenesulfonamide (6b)



Colorless liquid (47 mg, 98 %); ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, $J = 8.4$ Hz, 2H), 7.27 – 7.21 (m, 8H), 7.17 – 7.14 (m, 5H), 7.01 (t, $J = 7.6$ Hz, 1H), 6.88 (d, $J = 8.0$ Hz, 1H), 5.16 (d, $J = 15.6$ Hz, 1H), 4.97 (d, $J = 15.2$ Hz, 1H), 2.37 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.4 (d, $J = 22.6$ Hz), 142.4, 141.3 (d, $J = 5.1$ Hz), 139.5, 138.3, 134.5, 134.1 (d, $J = 26.1$ Hz), 130.8 (d, $J = 2.7$ Hz), 130.6 (d, $J = 21.0$ Hz), 129.2,

129.2, 128.9, 128.9, 128.0, 127.6, 126.8, 125.1, 124.5 (d, $J = 2.5$ Hz), 123.6 (d, $J = 6.3$ Hz), 110.3, 96.7 (d, $J = 198.3$ Hz), 46.1, 21.5, 21.3; IR (neat) ν 3062, 3031, 2923, 1627, 1592, 1513, 1487, 1470, 1455, 1392, 1351, 1318, 1300, 1209, 1182, 1155, 1050, 1009 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{29}\text{H}_{25}\text{FN}_2\text{O}_2\text{S}]$: 484.1621; found: 484.1624.


N-(3-Fluoro-1-methyl-3-phenylindolin-2-ylidene)-4-methylbenzenesulfonamide (6c)



White solid (38 mg, 95%); m.p. 175.8 – 177.0 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.61 (d, $J = 8.4$ Hz, 2H), 7.39 – 7.32 (m, 6H), 7.20 – 7.17 (m, 3H), 7.08 (t, $J = 7.6$ Hz, 1H), 6.95 (d, $J = 8.0$ Hz, 1H), 3.44 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.2 (d, $J = 22.4$ Hz), 142.5, 142.4 (d, $J = 5.2$ Hz), 139.6, 137.0 (d, $J = 26.0$ Hz), 131.1 (d, $J = 2.7$ Hz),


130.1 (d, $J = 20.5$ Hz), 129.0, 128.5, 128.5, 126.8, 125.1, 124.5 (d, $J = 2.5$ Hz), 123.8 (d, $J = 6.5$ Hz), 109.6, 96.8 (d, $J = 197.9$ Hz), 29.5, 21.5; IR (neat) ν 3063, 3024, 2920, 1633, 1592, 1493, 1471, 1450, 1382, 1364, 1317, 1303, 1197, 1156, 1088, 1019, 994 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{22}\text{H}_{19}\text{FN}_2\text{O}_2\text{S}]$: 394.1151; found: 394.1150

N-(3-Fluoro-3-(4-fluorophenyl)-1-methylindolin-2-ylidene)-4-methylbenzenesulfonamide (6d)




White solid (39 mg, 94 %); m.p. 163.5 – 164.4 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, J = 8.4 Hz, 2H), 7.39 (t, J = 8.0 Hz, 1H), 7.34 – 7.30 (m, 2H), 7.22 – 7.17 (m, 3H), 7.12 – 7.02 (m, 3H), 6.96 (d, J = 7.6 Hz, 1H), 3.44 (s, 3H), 2.39 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.9 (d, J = 22.7 Hz), 162.7 (d, J = 246.6 Hz), 163.8, 161.5, 161.5, 142.7, 142.5 (d, J = 5.3 Hz), 139.6, 132.9 (dd, J_1 = 26.7 Hz, J_2 = 3.3 Hz), 131.3 (d, J = 2.8 Hz), 129.8 (d, J = 20.1 Hz), 129.1, 126.7, 126.1 (d, J = 6.7 Hz), 126.0 (d, J = 6.6 Hz), 125.1, 124.7 (d, J = 2.6 Hz), 115.5 (d, J = 22.0 Hz), 109.7, 96.4 (d, J = 197.8 Hz), 29.6, 21.5; IR (neat) ν 3066, 3028, 2916, 1633, 1592, 1511, 1493, 1471, 1384, 1360, 1317, 1304, 1223, 1197, 1158, 1088, 1019, 996 cm^{-1} ; HRMS (ESI): $[\text{M}+\text{Na}]^+$ calcd for $[\text{C}_{22}\text{H}_{18}\text{F}_2\text{N}_2\text{NaO}_2\text{S}]^+$: 435.0949; found: 435.0947.

N-(3-(4-Bromophenyl)-3-fluoro-1-methylindolin-2-ylidene)-4-methylbenzenesulfonamide (6e)



White solid (45 mg, 96 %); m.p. 186.5 – 187.6 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.62 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.41 – 7.37 (m, 1H), 7.21 (d, J = 8.4 Hz, 4H), 7.15 (d, J = 7.6 Hz, 1H), 7.11 – 7.07 (m, 1H), 6.95 (d, J = 8.0 Hz, 1H), 3.44 (s, 3H), 2.39 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.7 (d, J = 22.5 Hz), 142.7, 142.5 (d, J = 5.0 Hz), 139.5, 136.1 (d, J = 26.4 Hz), 132.0, 131.7, 131.4 (d, J = 2.7 Hz), 129.6 (d, J = 20.4 Hz), 129.1, 127.7 (d, J = 43.5 Hz), 126.7, 125.7 (d, J = 6.5 Hz), 125.1, 124.7 (d, J = 2.4 Hz), 122.7, 109.7, 96.4 (d, J = 198.9 Hz), 29.6, 21.5; IR (neat) ν 3064, 2924, 1731, 1632, 1589, 1488, 1471, 1383, 1316, 1183, 1156, 1087, 1010 cm^{-1} ; HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{22}\text{H}_{19}\text{BrFN}_2\text{O}_2\text{S}]^+$: 473.0329; found: 473.0319.


N-(3-Fluoro-3-(4-methoxyphenyl)-1-methylindolin-2-ylidene)-4-methylbenzenesulfonamide (6f)



White solid (38 mg, 90 %); m.p. 189.1 – 190.2 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, J = 8.4 Hz, 2H), 7.37 (t, J = 8.0 Hz, 1H), 7.28 – 7.26 (m, 2H), 7.21 – 7.19 (m, 3H), 7.09 (t, J = 7.6 Hz, 1H), 6.94 (d, J = 7.6 Hz, 1H), 6.88 (d, J = 8.8 Hz, 2H), 3.81 (s, 3H), 3.45 (s, 3H), 2.39 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.3 (d, J = 22.7 Hz), 159.7, 142.5 (d, J = 5.2 Hz), 142.4, 139.8, 131.0 (d, J = 2.6 Hz), 130.2 (d, J = 20.7 Hz), 129.0, 128.9 (d, J = 26.7 Hz), 126.7, 125.5 (d, J = 6.3 Hz), 125.1, 124.5 (d, J = 2.5 Hz), 113.8, 109.6, 96.8 (d, J = 196.7 Hz), 55.2, 29.7, 21.5; IR (neat) ν 3058, 2935, 2839, 1631, 1593, 1514, 1490, 1471, 1385, 1360, 1316, 1302, 1254, 1179, 1157, 1088, 1031, 994 cm^{-1} ; HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{23}\text{H}_{22}\text{FN}_2\text{O}_3\text{S}]^+$: 425.1330;


found: 425.1314.

N-(3-Fluoro-1-methyl-3-(m-tolyl)indolin-2-ylidene)-4-methylbenzenesulfonamide (6g)




Colorless liquid (40 mg, 98 %); ^1H NMR (400 MHz, CDCl_3) δ 7.60 (d, J = 8.0 Hz, 2H), 7.36 (t, J = 8.0 Hz, 1H), 7.28 – 7.24 (m, 1H), 7.21 – 7.14 (m, 5H), 7.08 (t, J = 7.6 Hz, 2H), 6.94 (d, J = 8.0 Hz, 1H), 3.45 (s, 3H), 2.38 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.3 (d, J = 22.2 Hz), 142.5, 142.4 (d, J = 5.1 Hz), 139.6, 138.2 (d, J = 1.0 Hz), 136.9 (d, J = 25.9 Hz), 131.0 (d, J = 2.7 Hz), 130.2 (d, J = 20.8 Hz), 129.4, 129.0, 128.5 (d, J = 0.7 Hz), 126.8, 125.1 (d, J = 0.6 Hz), 124.5 (d, J = 2.5 Hz), 124.2 (d, J = 6.1 Hz), 120.9 (d, J = 6.6 Hz), 109.6, 96.8 (d, J = 197.7 Hz), 29.6, 21.5, 21.5; IR (neat) ν 3062, 2924, 2856, 1633, 1594, 1489, 1471, 1382, 1360, 1317, 1300, 1212, 1157, 1087, 1016, 990 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{23}\text{H}_{21}\text{FN}_2\text{O}_2\text{S}]$: 408.1308; found: 408.1307.

N-(3-(3,5-Dimethylphenyl)-3-fluoro-1-methylindolin-2-ylidene)-4-methylbenzenesulfonamide (6h)



White solid (38 mg, 91 %); m.p. 184.0 – 185.1 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.59 (d, J = 8.0 Hz, 2H), 7.35 (t, J = 8.0 Hz, 1H), 7.21 (d, J = 7.6 Hz, 1H), 7.17 (d, J = 8.0 Hz, 2H), 7.07 (t, J = 7.6 Hz, 1H), 6.95 – 6.91 (m, 4H), 3.45 (s, 3H), 2.37 (s, 3H), 2.27 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.3 (d, J = 22.1 Hz), 142.4, 142.3 (d, J = 5.1 Hz), 139.6, 138.1 (d, J = 1.0 Hz), 136.8 (d, J = 25.6 Hz), 130.9 (d, J = 21.3 Hz), 130.3, 130.1, 128.9, 126.8, 125.1, 124.5 (d, J = 2.5 Hz), 121.4 (d, J = 6.2 Hz), 109.6, 96.8 (d, J = 197.5 Hz), 29.6, 21.4, 21.4; IR (neat) ν 3067, 3028, 2920, 1633, 1591, 1493, 1471, 1382, 1360, 1317, 1300, 1222, 1157, 1132, 1088, 1016 cm^{-1} ; HRMS (EI): M^+ calcd for $[\text{C}_{24}\text{H}_{23}\text{FN}_2\text{O}_2\text{S}]$: 422.1464; found: 422.1458.


N-(3-Fluoro-1-methyl-3-(naphthalen-2-yl)indolin-2-ylidene)-4-methylbenzenesulfonamide (6i)



White solid (42 mg, 95 %); m.p. 164.2 – 165.1 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.83 – 7.45 (m, 4H), 7.51 – 7.47 (m, 4H), 7.39 – 7.35 (m, 2H), 7.06 (d, J = 7.6 Hz, 1H), 7.02 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 8.0 Hz, 1H), 3.50 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.2 (d, J = 22.4 Hz), 142.5 (d, J = 5.2 Hz), 142.4, 139.5, 134.2 (d, J = 25.9 Hz), 133.0 (d, J = 27.9 Hz), 131.2 (d, J = 2.7 Hz), 130.0 (d, J = 20.7 Hz), 129.0, 128.9,


128.5 (d, $J = 1.2$ Hz), 128.3, 127.7, 127.5 (d, $J = 8.2$ Hz), 126.7, 126.5 (d, $J = 6.3$ Hz), 125.2, 124.6 (d, $J = 2.5$ Hz), 123.1 (d, $J = 6.7$ Hz), 121.4 (d, $J = 6.2$ Hz), 109.7, 96.9 (d, $J = 198.4$ Hz), 29.6, 21.4; IR (neat) ν 3061, 2920, 1730, 1633, 1593, 1489, 1471, 1427, 1385, 1356, 1315, 1230, 1156, 1087, 1020 cm^{-1} ; HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{26}\text{H}_{22}\text{FN}_2\text{O}_2\text{S}]^+$: 445.1381; found: 445.1373.

N-(5-Bromo-3-fluoro-1-methyl-3-(p-tolyl)indolin-2-ylidene)-4-methylbenzenesulfonamide (6j)



White solid (48 mg, 99 %); m.p. 191.2 – 192.3 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.62 (d, $J = 8.4$ Hz, 2H), 7.49– 7.46 (m, 1H), 7.29– 7.28 (m, 1H), 7.22 – 7.17 (m, 6H), 6.81 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.2$ Hz, 1H), 3.41 (s, 3H), 2.38 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.8 (d, $J = 22.5$ Hz), 142.7, 141.4 (d, $J = 4.9$ Hz), 139.4, 138.8, 133.8 (d, $J = 2.5$ Hz), 133.5 (d, $J = 26.0$ Hz), 132.0 (d, $J = 21.0$ Hz), 129.4 (d, $J = 0.7$ Hz), 129.0, 128.3, 126.9, 123.7 (d, $J = 6.3$ Hz), 117.2 (d, $J = 2.9$ Hz), 111.0, 96.4 (d, $J = 198.9$ Hz), 29.6, 21.5, 21.3; IR (neat) ν 3024, 2923, 1731, 1622, 1594, 1510, 1488, 1417, 1356, 1317, 1282, 1258, 1184, 1158, 1088, 1020 cm^{-1} ; HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{23}\text{H}_{21}\text{FBrN}_2\text{O}_2\text{S}]^+$: 487.0486; found: 487.0462.

N-(3-Fluoro-5-methoxy-1-methyl-3-(p-tolyl)indolin-2-ylidene)-4-methylbenzenesulfonamide (6k)



White solid (36 mg, 81 %); m.p. 196.5 – 197.7 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.63 (d, $J = 8.4$ Hz, 2H), 7.22 (d, $J = 8.4$ Hz, 2H), 7.18 – 7.14 (m, 4H), 6.88– 6.83 (m, 2H), 6.77 (s, 1H), 3.72 (s, 3H), 3.43 (s, 3H), 2.37 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.2 (d, $J = 22.5$ Hz), 157.3 (d, $J = 2.6$ Hz), 142.3, 140.0, 138.4, 135.7 (d, $J = 5.3$ Hz), 134.0 (d, $J = 26.2$ Hz), 131.4 (d, $J = 20.3$ Hz), 129.2, 128.9, 126.7, 123.9 (d, $J = 6.4$ Hz), 115.7 (d, $J = 2.6$ Hz), 111.7, 110.3, 97.1 (d, $J = 197.9$ Hz), 55.8, 29.8, 21.4, 21.2; IR (neat) ν 2924, 2834, 1622, 1594, 1496, 1431, 1358, 1315, 1288, 1224, 1155, 1089, 1036, 1002 cm^{-1} ; HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{24}\text{H}_{24}\text{FN}_2\text{O}_3\text{S}]^+$: 439.1486; found: 439.1474.

The ^1H and ^{13}C NMR Spectra of Products

